First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
Speranza G, Anderson L, Chen AP, Do K, Eugeni M, Weil M, Rubinstein L, Majerova E, Collins J, Horneffer Y, Juwara L, Zlott J, Bishop R, Conley BA, Streicher H, Tomaszewski J, Doroshow JH, Kummar S.
Speranza G, et al. Among authors: horneffer y.
Invest New Drugs. 2018 Apr;36(2):230-239. doi: 10.1007/s10637-017-0495-3. Epub 2017 Aug 12.
Invest New Drugs. 2018.
PMID: 28808818
Free PMC article.
Clinical Trial.